The Essential

Tekne Capital’s Beeneet Kothari Plays the Long Game — and Wins Big on China Tech

Tekne Capital’s founder is doubling down on Chinese innovation—betting that the country’s cheap, under-owned tech stocks’ global comeback is just starting.

Biopharma’s Remarkable Reversal of Fortune

Life sciences and biopharma hedge funds have been on a tear for the past few months. Can it continue?

Sponsored

Your Alternatives Need an Alternative

How Kathleen Vogelsang Built Van Andel’s Endowment from Scratch — And Is Now Guiding Others

After two decades leading the $2.3B portfolio, the organization’s debut CIO is launching an advisory firm for investors starting from zero.

Related Content

China’s Not the Only Emerging Market With Stocks Trading at a Discount

Hannah Zhang

Is Tiger Global’s China Hustle Over?

Michelle Celarier

What Top Research Providers Expect from China’s Reopening

Grace Chung

Job Board – For Investors Only

Investment Analyst
​

University of Virginia

​
Learn More

Investment Analyst
​

DUMAC Inc

​
Learn More

Investment Analyst
​

DUMAC Inc

​
Learn More

Investment Analyst
​

BlueCross BlueShield Association

​
Learn More

1270 Avenue of the Americas, Suite 1120

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X
Bluesky
Instagram